AI systems for the pharmaceutical industry, medical devices and clinical research

R&D teams spend full days navigating thousands of clinical documents scattered across disconnected systems, at risk of missing critical data. This secure RAG centralizes trial protocols, clinical results and regulatory references with traceable citations and role-based access control. Estimated 65% reduction in document retrieval time during pilot phases.

Researchers spend several weeks mapping a therapeutic domain, at risk of missing key clinical publications. This RAG copilot indexes multilingual scientific literature, synthesizes themes and maps relationships between studies. Literature review time reduced from 6 weeks to 4 days in pilot evaluations.

Late detection of adverse events exposes organizations to major regulatory and patient risks. This system analyzes pharmacovigilance reports in real time, detects weak signals and prioritizes alerts for medical teams. Critical signal detection delay reduced from 12 days to 48 hours.

Drafting a clinical trial protocol takes several months and mobilizes costly experts, with risk of deviations from regulatory standards. This generator produces protocols aligned with ICH, FDA and EMA standards, from historical data and therapeutic requirements. Drafting cycle reduced from 4 months to 3 weeks in pilot scenarios.

Automated identification of candidate biomarkers from genomic, proteomic and clinical data to accelerate translational research.

Reduces biomarker candidate identification time from 18 months to 6 months.

Automatic identification and qualification of patient cohorts eligible for clinical trials from medical records.

Multiplies clinical trial recruitment speed by 3.

Preparing FDA, EMA and SwissMedic regulatory dossiers mobilizes entire teams for months, with high error and non-compliance rates. This agent automatically verifies dossier compliance, identifies gaps and generates structured audit reports. Regulatory preparation time reduced by 70% and supplement requests reduced by 55%.

GxP documentation (GMP, GCP, GLP) is a time-consuming and critical process, where each drafting error can lead to non-conformities during audits. This assistant generates, validates and updates regulatory documentation in compliance with international standards. GxP documentation time reduced by 60% and audit compliance rate of 98%.

Visual quality control in pharmaceutical production is still largely manual, with false negative rates incompatible with regulatory requirements. This computer vision system detects visual non-conformities in real time on production lines. Undetected defects reduced by 94% and inspection throughput increased by 300%.

Automated analysis of audit trails to detect compliance anomalies before regulatory inspections.

Reduces critical audit findings by 80%.

Automatic verification of label and packaging compliance with regulatory requirements by market and language.

Reduces product recalls linked to labeling errors by 90%.

Critical drug shortages result from insufficient supply chain visibility, with direct consequences on patients and regulatory penalties. This system predicts shortage risks 8 to 12 weeks ahead and optimizes inventory levels in real time. Shortages reduced by 75% and overstock reduced by 40%.

Cold chain breaks represent losses of several million euros and major patient risks, often detected too late to allow intervention. This agent monitors transport and storage conditions in real time, generates predictive alerts and automatically documents deviations. Product losses linked to cold chain reduced by 85%.

Pharmaceutical manufacturing processes generate massive volumes of unexploited sensor data, leaving inefficiencies and quality risks undetected. This system analyzes production data in real time to identify drifts, optimize parameters and prevent unplanned stops. Production yield increased by 22% and rejects reduced by 60%.

Continuous supplier risk assessment across quality, regulatory, financial and geopolitical criteria to secure the supply chain.

Reduces critical supplier incidents by 70%.

End-to-end serialization and traceability platform for pharmaceutical batches compliant with DSCSA and FMD requirements.

Regulatory traceability compliance achieved on 100% of batches.

Real-world data is underexploited by the pharmaceutical industry, lacking infrastructure to collect, clean and analyze at scale. This platform aggregates and analyzes real-world data to generate evidence complementing clinical trials. RWE evidence generation time reduced from 18 months to 4 months.

Data from connected medical devices is collected but rarely exploited to improve treatments or detect safety signals. This platform centralizes, normalizes and analyzes device data in real time with safety alerts and therapeutic insights. Device safety signal detection 8 times faster than manual.

Therapeutic non-adherence represents billions in annual losses for the industry and major risks for patients. This system identifies patients at risk of non-adherence and personalizes follow-up interventions. Adherence rate improved by 35% in pilot programs.

Continuous monitoring of digital biomarkers via wearables and mobile applications for therapeutic follow-up and early relapse detection.

Unplanned hospitalizations reduced by 40%.

Automatic identification and qualification of patients eligible for early access and compassionate use programs.

Delay in accessing innovative treatments reduced by 60%.

Modeling the medico-economic impact of therapeutic innovations to accelerate negotiations with payers and health authorities.

Payer negotiation cycle reduced from 12 months to 4 months.

Patient-treatment matching based on genomic, clinical and behavioral profile for precision medicine and oncology.

Therapeutic response rate improved by 45%.

Automated post-market surveillance from regulatory databases, social networks and medical publications.

Post-market signal detection delay reduced by 80%.